<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00515957</url>
  </required_header>
  <id_info>
    <org_study_id>20996</org_study_id>
    <secondary_id>20996-DELLA</secondary_id>
    <nct_id>NCT00515957</nct_id>
  </id_info>
  <brief_title>Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)</brief_title>
  <acronym>DELLA</acronym>
  <official_title>Administration of LMP1- and LMP2-Specific Cytotoxic T-Lymphocytes Following CD45 Antibody Administration to Patients With EBV-Positive Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Cell and Gene Therapy, Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study NPC patient will receive 4 days of treatment with CD45 antibody followed by one&#xD;
      dose of LMP1- and LMP2-CTL. From this, we can learn if treating the patient first with the&#xD;
      CD45 antibody will also let LMP1- and LMP2-CTL we give grow better. In addition, we will find&#xD;
      out, if LMP1- and LMP2-CTL are safe and have enhanced anti-tumor activity in comparison to&#xD;
      standard EBV-CTL.&#xD;
&#xD;
      This study aims to determine the safety of autologous LMP1- and LMP2- specific cytotoxic&#xD;
      T-lymphocytes (CTL) in combination with CD45 monoclonal antibody (MAb) in patients with&#xD;
      EBV-positive nasopharyngeal carcinoma (NPC).&#xD;
&#xD;
      And to obtain information on the expansion, persistence and anti-tumor effects of autologous&#xD;
      LMP1- and LMP-2 specific CTL given after lymphodepletion with CD45 MAb in patients with&#xD;
      EBV-positive NPC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While patients with nasopharyngeal carcinoma (NPC) may be cured by chemotherapy and&#xD;
      radiotherapy, the outlook for patients who are resistant to this treatment or who relapse is&#xD;
      poor. Almost all patients with undifferentiated nasopharyngeal carcinoma have the EBV virus&#xD;
      in their tumors which may be a target for immunotherapy approaches. We have successfully used&#xD;
      specialized immune system cells grown in the laboratory and trained to recognize and kill EBV&#xD;
      infected cells (EBV-specific cytotoxic T-lymphocytes [EBV-CTL]) to prevent and treat another&#xD;
      type of cancer called post transplant lymphoma that occurs after bone marrow transplant. In&#xD;
      post transplant lymphoma, the tumor cells have 9 proteins made by EBV on their surface.&#xD;
      However in nasopharyngeal carcinoma that develops in patients with a normal immune system,&#xD;
      the tumor cells only express 2 EBV proteins that are much harder for the immune system to&#xD;
      recognize. In a previous study we made EBV-CTL that recognized all 9 proteins and gave them&#xD;
      to patients with NPC. For patients without evidence of active disease at the time of therapy,&#xD;
      there disease remains in remission. For those patients with active disease at the time they&#xD;
      received CTL, some patients had a partial response to this therapy, and only three patients&#xD;
      had a complete response. We think the main reason for this is that many of the T cells&#xD;
      reacted with EBV proteins that were not on the tumor cells, and the other is that the infused&#xD;
      T cells have not enough space to grow.&#xD;
&#xD;
      The two EBV proteins present on NPC tumor cells that are good targets for T-cell therapies&#xD;
      are called LMP1 and LMP2. We are therefore planing to generate T cells specific for LMP1 and&#xD;
      LMP2 and infuse these cells into NPC patients. To make LMP1- and LMP2-CTL, we have obtained&#xD;
      blood from the patients and grown special type of cell called a dendritic cell (DC) and EBV&#xD;
      infected lymphoblastoid cells (LCL). We have then transferred an adenovirus vector that&#xD;
      carries the LMP1 and LMP2 gene into the DC and the LCL. These DC and LCL are then treated&#xD;
      with radiation so they cannot grow and are used to stimulate and expand LMP1- and LMP2-CTL.&#xD;
      This stimulation trains the T cells to kill cancer cells with LMP1 and LMP2 on their surface.&#xD;
&#xD;
      To 'create space' for EBV-CTL growth after infusion in NPC patients we have already used a&#xD;
      special protein called a CD45 antibody, which removes for a short period of time most of the&#xD;
      patient's T cells. The preliminary results of this study is encouraging: the use of the CD45&#xD;
      antibody is safe and we observed enhanced EBV-CTL growth after infusion. In addition, all&#xD;
      patients who has EBV-CTL growth had clinical responses.&#xD;
&#xD;
      We and others have demonstrated the feasibility of CTL therapy for EBV-positive NPC in&#xD;
      immunocompetent patients, providing preliminary evidence of anti-tumor activity of EBV-CTL in&#xD;
      this patient population. Not all patients responded, however, suggesting the need for further&#xD;
      improvement. We propose that CTL failure can be overcome by increasing the specificity of the&#xD;
      infused CTL product. That is, infusion of CTL specific for LMP1 and LMP2 will produce greater&#xD;
      clinical benefit than EBV-specific CTL. The rationale for this approach is straight forward:&#xD;
      EBV-specific CTL lines generated by standard methods are dominated by T-cell clones not&#xD;
      reactive to the subdominant EBV proteins LMP1 and LMP2 expressed in NPC. We also propose that&#xD;
      the failure of adoptively transferred CTL to measurably expand in the peripheral blood of NPC&#xD;
      patients is a consequence both of lymphoid homeostasis in these lympho-replete patients and&#xD;
      of the inhibitory T-cell infiltrate at the sites of disease. We will therefore use monoclonal&#xD;
      antibodies targeting the CD45 antigen (CD45 MAbs), to lymphodeplete NPC patients prior to the&#xD;
      infusion of EBV-specific CTL. Preliminary results indicate that CD45 MAb depletion can&#xD;
      augment CTL expansion, and that such expansion is associated with a higher disease response&#xD;
      rate. We will confirm and extend these promising new data in this Phase I clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety of autologous LMP1- and LMP2- specific cytotoxic T-lymphocytes (CTL) in combination with CD45 monoclonal antibody (MAb) in patients with EBV-positive nasopharyngeal carcinoma (NPC).</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To obtain information on the expansion, persistence and anti-tumor effects of autologous LMP1- and LMP-2 specific CTL given after lymphodepletion with CD45 MAb in patients with EBV-positive NPC.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>NASOPHARYNGEAL CARCINOMA</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Nasopharyngeal Carcinoma in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV-genome or antigens have been demonstrated in tissue biopsies</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>genetically modified CTLs in combo with CD45 antibodies</intervention_name>
    <description>LMP1- and LMP2- specific cytotoxic T-lymphocytes (CTL) in combination with CD45 monoclonal antibody (MAb).&#xD;
--Infusions of CD45 MAbs: A fixed dose of CD45 MAbs will be used determined from our previous and ongoing studies in stem cell transplant recipients will be used43, 400ug/kg over 6 to 8 hrs daily x 4 given as 4 daily intravenous infusions that will be completed 48-72 hours prior to CTL infusion.&#xD;
Day 1 YTH 24/54 400ug/kg over 6 to 8 hr 2 YTH 24/54 400ug/kg over 6 to 8 hr 3 YTH 24/54 400ug/kg over 6 to 8 hr 4 YTH 24/54 400ug/kg over 6 to 8 hr 5 Rest 6-8 CTL Infusion (provided CD45 MAb level &lt;100 ng/ml)&#xD;
--LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.&#xD;
2x 10^7 cells/m2&#xD;
1x 10^8 cells/m2 3 x 10^8 cells/m2&#xD;
1 x 10^9 cells/m2</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients with NPC in first or subsequent relapse or with primary refractory disease or&#xD;
        high risk (T3 or T4, or node positive) in whom the EBV genome or antigens have been&#xD;
        demonstrated in tissue biopsies will be eligible for this trial.&#xD;
&#xD;
        Any patient with EBV positive NPC, in relapse or with primary resistant disease&#xD;
&#xD;
        Patients with a life expectancy 6 weeks or greater.&#xD;
&#xD;
        Patients with a Karnofsky score (age at least 16; for Karnofsky scale see full protocol) or&#xD;
        Lansky score (less than 16; for Lansky scale see full protocol) of 50 or greater as&#xD;
        described below:&#xD;
&#xD;
        Patients with bilirubin &lt;2x normal, SGOT &lt;3x normal, and Hgb greater than 8.0.&#xD;
&#xD;
        Patients with a creatinine 2x normal or less for age.&#xD;
&#xD;
        Patients should have been off other investigational therapy for one month prior to entry in&#xD;
        this study.&#xD;
&#xD;
        Patient, parent/guardian able to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Severe intercurrent infection.&#xD;
&#xD;
        Due to unknown effects of this therapy on a fetus, pregnant women are excluded from this&#xD;
        research. The male partner should use a condom.&#xD;
&#xD;
        Note: Patients who would be excluded from the protocol strictly for laboratory&#xD;
        abnormalities can be included at the investigatorÂ¡-s discretion after approval by the CCGT&#xD;
        Protocol Review Committee and the FDA reviewer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Gottschalk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>August 10, 2007</study_first_submitted>
  <study_first_submitted_qc>August 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2007</study_first_posted>
  <last_update_submitted>April 13, 2012</last_update_submitted>
  <last_update_submitted_qc>April 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Stephen Gottschalk</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

